Trial Profile

A Phase 1 Study of Inhaled KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KB 408 (Primary)
Indications Alpha 1-antitrypsin deficiency
Focus Adverse reactions; Proof of concept
Acronyms Serpentine-1
Sponsors Krystal Biotech

Most Recent Events

17 Feb 2026 According to a Krystal Biotech media release, The Company continues to enroll patients in the repeat dose Cohort 2B of SERPENTINE-1, the Company's open label dose escalation study evaluating KB408.
03 Nov 2025 According to a Krystal Biotech media release, company expects to report interim data for this cohort in 1H 2026.
04 Aug 2025 According to a Krystal Biotech media release, first patient in Cohort 2B was dosed earlier this month.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com